+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Fluorescence assays for monitoring RNA-ligand interactions and riboswitch-targeted drug discovery screening



Fluorescence assays for monitoring RNA-ligand interactions and riboswitch-targeted drug discovery screening



Methods in Enzymology 550: 363-383



Riboswitches and other noncoding regulatory RNA are intriguing targets for the development of therapeutic agents. A significant challenge in the drug discovery process, however, is the identification of potent compounds that bind the target RNA specifically and disrupt its function. Essential to this process is an effectively designed cascade of screening assays. A screening cascade for identifying compounds that target the T box riboswitch antiterminator element is described. In the primary assays, moderate to higher throughput screening of compound libraries is achieved by combining the sensitivity of fluorescence techniques with functionally relevant assays. Active compounds are then validated and the binding to target RNA further characterized in secondary assays. The cascade of assays monitor ligand-induced changes in the steady-state fluorescence of an attached dye or internally incorporated 2-aminopurine; the fluorescence anisotropy of an RNA complex; and, the thermal denaturation fluorescence profile of a fluorophore-quencher labeled RNA. While the assays described have been developed for T box riboswitch-targeted drug discovery, the fluorescence methods and screening cascade design principles can be applied to drug discovery efforts targeted toward other medicinally relevant noncoding RNA.

(PDF emailed within 0-6 h: $19.90)

Accession: 057887258

Download citation: RISBibTeXText

PMID: 25605395

DOI: 10.1016/bs.mie.2014.10.040


Related references

Drug-drug interactions of anti-infective drugs: utility of fluorescence cyp inhibition assays in drug discovery. Drug Metabolism and Drug Interactions 21(3-4): 163-185, 2006

Receptor-ligand interactions studied with homogeneous fluorescence-based assays suitable for miniaturized screening. Journal of Biomolecular Screening 6(1): 11-18, 2001

Riboswitch-based antibacterial drug discovery using high-throughput screening methods. Expert Opinion on Drug Discovery 8(1): 65-82, 2013

Development of high throughput screening assays using fluorescence polarization: Nuclear receptor-ligand-binding and kinase/phosphatase assays. Journal of Biomolecular Screening 5(2): 77-88, April, 2000

Discovery of New E-Selectin Inhibitors by Virtual Screening, Fluorescence Binding Assays, and STD NMR Experiments. Chemmedchem 11(9): 1008-1014, 2016

Development and application of fluorescence polarization assays in drug discovery. Combinatorial Chemistry & High Throughput Screening 6(3): 183-194, 2003

Fluorescence lifetime assays: current advances and applications in drug discovery. Expert Opinion on Drug Discovery 6(6): 663-670, 2012

Models and screening assays for drug discovery in osteoporosis. Expert Opinion on Drug Discovery 5(12): 1163-1174, 2010

Data quality in drug discovery: the role of analytical performance in ligand binding assays. Journal of Computer-Aided Molecular Design 29(9): 847-865, 2016

Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. Analytical Biochemistry 356(2): 273-281, 2006

Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery. Journal of Biomolecular Screening 13(5): 343-353, 2008

Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Analytical Biochemistry 332(1): 153-159, 2004

Homogenous, equilibrium binding assays using fluorescence polarization for basic research and drug discovery. FASEB Journal 12(8): A1490, April 24, 1998